Importance of glycolysis and oxidative phosphorylation in advanced melanoma.

PubWeight™: 1.10‹?› | Rank: Top 10%

🔗 View Article (PMC 3537610)

Published in Mol Cancer on October 09, 2012

Authors

Jonhan Ho1, Michelle Barbi de Moura, Yan Lin, Garret Vincent, Stephen Thorne, Lyn M Duncan, Lin Hui-Min, John M Kirkwood, Dorothea Becker, Bennett Van Houten, Stergios J Moschos

Author Affiliations

1: Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA.

Articles citing this

Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta (2013) 1.85

Mitochondria, energetics, epigenetics, and cellular responses to stress. Environ Health Perspect (2014) 1.03

Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res (2014) 0.98

Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy. Cell Rep (2016) 0.98

CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle (2013) 0.89

Overexpression of mitochondrial sirtuins alters glycolysis and mitochondrial function in HEK293 cells. PLoS One (2014) 0.88

Cancer stem cell theory and the warburg effect, two sides of the same coin? Int J Mol Sci (2014) 0.87

A bioenergetic profile of non-transformed fibroblasts uncovers a link between death-resistance and enhanced spare respiratory capacity. Mitochondrion (2013) 0.85

Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. BMC Cancer (2016) 0.81

WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis (2013) 0.81

Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities? Acta Neuropathol Commun (2014) 0.80

Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. Chin J Cancer (2014) 0.79

Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Exp Dermatol (2015) 0.79

WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. Oncogene (2017) 0.77

Metabolic rewiring in melanoma. Oncogene (2016) 0.76

Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics. Int J Cell Biol (2015) 0.76

The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle (2016) 0.75

MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. Int J Clin Exp Pathol (2015) 0.75

Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation. Cell Cycle (2016) 0.75

Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget (2016) 0.75

Mitochondrial targeted β-lapachone induces mitochondrial dysfunction and catastrophic vacuolization in cancer cells. Bioorg Med Chem Lett (2015) 0.75

Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular Ascorbate. Front Oncol (2014) 0.75

MicroRNA-33b inhibits cell proliferation and glycolysis by targeting hypoxia-inducible factor-1α in malignant melanoma. Exp Ther Med (2017) 0.75

Articles cited by this

Hallmarks of cancer: the next generation. Cell (2011) 140.01

On the origin of cancer cells. Science (1956) 49.55

Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52

Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem (1996) 7.37

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33

HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31

A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79

The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem (2006) 3.21

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol (2000) 2.86

The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J (2000) 2.59

Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26

Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem (2011) 2.24

Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A (2011) 2.06

Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods (2010) 1.62

Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen (2010) 1.60

Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res (1989) 1.60

Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther (2002) 1.57

Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res (2012) 1.46

Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog (2012) 1.40

Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol (2010) 1.16

Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One (2012) 1.12

Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol (2010) 1.05

LDH and melanoma. Cancer (1983) 0.96

Mitochondrial respiration--an important therapeutic target in melanoma. PLoS One (2012) 0.95

Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci (2010) 0.93

Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death. Biochem Biophys Res Commun (2010) 0.92

Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol (2009) 0.90

Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res (2010) 0.89

Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation. Cancer Biol Ther (2009) 0.87

Hypoxic mitochondria: accomplices in resistance. Bull Cancer (2011) 0.83

Lactate dehydrogenase isoenzyme pattern in sera of patients with malignant diseases. Clin Chem (1989) 0.81

Serum lactate dehydrogenase isoenzymes in breast tumours. Indian J Pathol Microbiol (1990) 0.80

A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers. PLoS One (2012) 0.80

Separation of five isoenzymes of serum lactate dehydrogenase by discontinuous gradient elution from a miniature ion-exchange column. Clin Chem (1979) 0.80

Combined chemotherapy or biotherapy with jasmonates: targeting energy metabolism for cancer treatment. Curr Pharm Biotechnol (2013) 0.79

The Warburg Hypothesis and the ATP Supply In Cancer Cells Is Oxidative Phosphorylation impaired in malignant neoplasias? Curr Pharm Biotechnol (2012) 0.78

Articles by these authors

(truncated to the top 100)

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78

Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55

Identification of cells initiating human melanomas. Nature (2008) 8.28

Genomewide association study of leprosy. N Engl J Med (2009) 8.17

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23

Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science (2010) 6.04

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79

Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64

Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47

Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer (2004) 3.46

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00

DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res (2008) 2.94

Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem (2004) 2.90

Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89

Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. Methods Mol Biol (2006) 2.87

Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell (2011) 2.84

Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer (2009) 2.78

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77

Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65

Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One (2011) 2.64

Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology (2010) 2.55

Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50

Hydrogen exchange methods to study protein folding. Methods (2004) 2.47

Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43

Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41

Prokaryotic nucleotide excision repair: the UvrABC system. Chem Rev (2006) 2.37

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26

Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol (2005) 2.22

Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep (2011) 2.20

An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15

Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res (2013) 2.15

Basal transcription defect discriminates between xeroderma pigmentosum and trichothiodystrophy in XPD patients. Mol Cell (2003) 2.12

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2008) 2.09

Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol (2012) 2.08

Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05

DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res (2013) 2.01

The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00

Case records of the Massachusetts General Hospital. Case 23-2014. A 41-year-old man with fevers, rash, pancytopenia, and abnormal liver function. N Engl J Med (2014) 2.00

Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99

Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97

Global analysis of the mitochondrial N-proteome identifies a processing peptidase critical for protein stability. Cell (2009) 1.96

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95

An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90

Integrating phenotypic and expression profiles to map arsenic-response networks. Genome Biol (2004) 1.90

High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89

Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta (2013) 1.85

Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83

Crystal structure of the FeS cluster-containing nucleotide excision repair helicase XPD. PLoS Biol (2008) 1.81

Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair. Nature (2011) 1.80

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77

IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice. J Clin Invest (2011) 1.77

Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One (2012) 1.76

IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76

Role of mitochondria in toxic oxidative stress. Mol Interv (2005) 1.76

Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One (2009) 1.71

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res (2009) 1.71

Next generation of immunotherapy for melanoma. J Clin Oncol (2008) 1.69

Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population. Atherosclerosis (2011) 1.64

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64

Association of inorganic arsenic exposure with type 2 diabetes mellitus: a meta-analysis. J Epidemiol Community Health (2013) 1.63

Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther (2005) 1.63

Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods (2010) 1.62

NIEHS extramural global environmental health portfolio: opportunities for collaboration. Environ Health Perspect (2008) 1.61

Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen (2010) 1.60

Mitochondrial DNA repair and aging. Mutat Res (2002) 1.60

Screening of patients with tuberculosis for diabetes mellitus in China. Trop Med Int Health (2012) 1.58

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol (2007) 1.57

Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55

Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle (2011) 1.54

An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics (2012) 1.54

Structural basis for DNA recognition and processing by UvrB. Nat Struct Mol Biol (2006) 1.51

A pilot study of heel ultrasound to screen for low bone mass in children with leukemia. J Pediatr Hematol Oncol (2006) 1.50

Cell sorting experiments link persistent mitochondrial DNA damage with loss of mitochondrial membrane potential and apoptotic cell death. J Biol Chem (2002) 1.49

Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One (2011) 1.48

Detecting disease-associated genes with confounding variable adjustment and the impact on genomic meta-analysis: with application to major depressive disorder. BMC Bioinformatics (2012) 1.46

Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem (2010) 1.46

The beta -hairpin motif of UvrB is essential for DNA binding, damage processing, and UvrC-mediated incisions. J Biol Chem (2001) 1.46